Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
'Dancing with the Stars' semifinals: How to watch Episode 10 tonight, where to stream, who's left and more - 2Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
- 3FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- 4Israeli Chief of Staff declares new border with Gaza Strip
- 5Pick Your #1 breakfast food
- Multi-million-euro win in Spanish lottery in doubt due to oversight
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- More parents refusing this shot that prevents serious bleeding at birth
- Robert Irwin on winning 'Dancing With the Stars' 10 years after sister Bindi: 'This was everything I dreamed it would be and so much more'
- ‘More should be done’: UN pushes Syrian regime on justice for Druze, Alawites and minority groups
- I decided to become a single mother by choice. I wasn't ready to stop dating.
- Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- Rescuers again fail to free whale stranded on Germany's Baltic coast
- Step by step instructions to Think about Disc Rates Across Various Banks
